Scholars Central

Conference abstractPublished 7 Nov 2016

Why are not biosimilars generics-regulatory challenges?

Authors: Adam Sabouni

PharmaConsultz, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

A consent decree is an agreement between the FDA and a pharmaceutical manufacturer that usually bars the drugmaker from manufacturing and distribution product(s) until the company has implemented timely and sustainable changes, through a series of steps, to bring the drug manufacturer in alignment with the FDA’s vision of GMPs. While there is no set formula for what triggers a consent decree, it is safe to assume that many consent decrees were/are caused by FDA inspections in which a company is found not following GMPs, followed by a warning letter. This presentation provides an overview and practical examples of what causes a company to fall under a consent decree, how to avoid it, and what is the best action plan to get out of it.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Developing Drugs.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Developing Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Adam Sabouni”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels